Highest-materiality recent filing
CG Oncology Q1 net loss widens to $60.2M; BLA submission on track for Q4 2026
Net loss of $60.2M ($0.71 per share) vs $34.5M ($0.45) in Q1 2025.
CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029
Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
CG Oncology ups ATM equity offering capacity by $300M to $550M
Filing increases aggregate offering of common stock under Open Market Sale Agreement from $250M to $550M.
PIVOT-006 topline data for cretostimogene in intermediate-risk NMIBC now expected in first half of 2026, nearly one year ahead of schedule.
CG Oncology Q3 net loss $43.8M ($0.57/share); initiates BLA for cretostimogene
Net loss of $43.8M ($0.57 per share) for Q3 2025 vs $20.4M ($0.30) in Q3 2024.
CG Oncology reports 41.8% 24-month CR in Phase 3 BOND-003 for cretostimogene
24-month CR rate of 41.8% (46/110) in BCG-unresponsive HR NMIBC; 12 additional CRs since April 2025 AUA.
CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR
Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.
CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025
Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo
BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%
Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
83 of 110 patients (75.5%) achieved complete response at any time in BOND-003 for BCG-unresponsive NMIBC with CIS.
CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months
74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).
CG Oncology Q3 net loss $20.4M; cash $540.7M, runway through 2027
Net loss of $20.4M ($0.30 per share) vs $17.5M ($4.00) in Q3 2023.
Net loss of $18.9M ($0.28 EPS) vs $11.6M loss ($3.93 EPS) in Q2 2023; R&D spend $18.5M vs $9.8M YoY.
CG Oncology reports 54% CR at 24 months for cretostimogene combo in NMIBC
Phase 2 CORE-001 final results: 54% (19/35) complete response rate at 24 months in BCG-unresponsive HR-NMIBC with CIS.
Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).
CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC
75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.
CG Oncology completes IPO of 23M shares at $19.00, raising $437M gross
IPO closed on Jan 29, 2024: 23M shares (includes full exercise of underwriters' option for 3M additional shares) at $19.00/share.
On May 20, 2026, the Company’s Board of Directors also approved the appointment of Arthur Kuan as President of the Company, in addition to his other positions, in connection with Mr. Bellete’s separation.
On May 20, 2026, CG Oncology, Inc. (the “ Company ”) and Ambaw Bellete, the Company’s President & Chief Operating Officer of the Company, agreed to his separation from the Company to be effective June 30, 2026.
Max materiality 0.85 · Median 0.68 · Most common event other_material